^
    Back
    Association details:
    Biomarker:CD19 positive
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:ISIKOK-19 (CD19-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Turk J Haematol
    Title:

    Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) targeting CD19-expressing B Cells for the First Turkish Academic Clinical Trial with Relapsed/refractory ALL and NHL Patients

    Published date:
    08/04/2020
    Excerpt:
    Relapsed and refractory CD19 positive B-cell acute lymphoblastic leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) are the focus of studies in hematological cancers…In addition, ISIKOK-19 cells demonstrated a significant high level of cytotoxicity specifically against a CD19+ B-lymphocyte cancer model, RAJI cells, in NOD/SCID mice. This is the first report of preclinical assessment of efficacy and safety analysis of CAR-T cells (ISIKOK-19) targeting CD19-expressing B cells in relapsed/refractory ALL and NHL patients in Turkey.
    DOI:
    10.4274/tjh.galenos.2020.2020.0070